Gilenya® shows long-term efficacy and safety - study

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Gilenya® shows long-term efficacy and safety - study

Postby MSUK » Sun Jun 10, 2012 11:55 pm

Gilenya® shows long-term efficacy and safety in extension of phase III head-to-head study

Image

New long-term data for Gilenya® (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment. These results, from an extension of the phase III head-to-head TRANSFORMS study, also showed improved efficacy for patients switched to Gilenya from Avonex® (interferon-beta-1a IM), a commonly prescribed MS treatment.

"These data further reinforce our confidence in Gilenya's long-term effectiveness and safety profile. The TRANSFORMS extension study shows that MS patients treated continuously with Gilenya for up to four and a half years demonstrated sustained low levels of clinical and MRI activity," said Tim Wright, Global Head of Development, Novartis Pharma. "Furthermore, patients who switched to Gilenya from interferon beta-1a IM showed a reduction in relapses and improvements in MRI measures in the extension compared to the core study."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 1981
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users